Vident Investment Advisory’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-4,338
| Closed | -$416K | – | 1226 |
|
|
2021
Q3 | $416K | Sell |
4,338
-615
| -12% | -$59K | 0.01% | 926 |
|
|
2021
Q2 | $482K | Buy |
4,953
+279
| +6% | +$27.2K | 0.01% | 843 |
|
|
2021
Q1 | $455K | Sell |
4,674
-369
| -7% | -$35.9K | 0.02% | 815 |
|
|
2020
Q4 | $483K | Sell |
5,043
-2,698
| -35% | -$258K | 0.02% | 727 |
|
|
2020
Q3 | $744K | Sell |
7,741
-2,523
| -25% | -$242K | 0.04% | 572 |
|
|
2020
Q2 | $1.25M | Buy |
10,264
+3,805
| +59% | +$464K | 0.07% | 400 |
|
|
2020
Q1 | $559K | Sell |
6,459
-75
| -1% | -$6.49K | 0.04% | 552 |
|
|
2019
Q4 | $702K | Sell |
6,534
-824
| -11% | -$88.5K | 0.04% | 466 |
|
|
2019
Q3 | $663K | Buy |
7,358
+747
| +11% | +$67.3K | 0.06% | 252 |
|
|
2019
Q2 | $558K | Buy |
6,611
+639
| +11% | +$53.9K | 0.04% | 297 |
|
|
2019
Q1 | $526K | Buy |
5,972
+1,512
| +34% | +$133K | 0.03% | 558 |
|
|
2018
Q4 | $318K | Buy |
4,460
+476
| +12% | +$33.9K | 0.02% | 697 |
|
|
2018
Q3 | $490K | Sell |
3,984
-640
| -14% | -$78.7K | 0.02% | 701 |
|
|
2018
Q2 | $454K | Buy |
4,624
+52
| +1% | +$5.11K | 0.02% | 689 |
|
|
2018
Q1 | $345K | Buy |
4,572
+1,898
| +71% | +$143K | 0.01% | 756 |
|
|
2017
Q4 | $207K | Buy |
+2,674
| New | +$207K | 0.01% | 763 |
|